MindMed – executive interview with Rob Barrow, CEO

MindMed is a clinical-stage US biopharmaceutical company aiming to leverage psychedelic medicines to target life-debilitating mental health conditions such as anxiety, ADHD and autism. Its most advanced clinical programmes are investigating the use of LSD D-tartrate (MM-120) for treating generalised anxiety disorder (GAD) and attention-deficit hyperactivity disorder (ADHD). The Phase IIb GAD trial is a randomised dose-finding study that will recruit up to 200 patients and is expected to deliver top-line results in H223. The Phase IIa proof-of-concept study in ADHD will assess the safety and efficacy of low-dose MM-120 as treatment for ADHD in adults, with readouts anticipated in H223. Additionally, the company will initiate a Phase I study in 2023 investigating R-MDMA for treating autism spectrum disorder. MindMed is also looking to use digital platforms to provide scalable, accessible and safe psychedelic treatment solutions to patients, overcoming resourcing constraints faced by healthcare providers and promoting adoption.

In this video, Rob Barrow, MindMed’s chief executive officer, provides background on the company’s use of psychedelic treatments and its developmental pipeline, highlighting the near-term priorities and plans.